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SObjectives: Our objective was to determine the long-term survival of patients with resected synchronous mul-
tiple pulmonary malignant tumors.
Methods: This is a multi-institutional retrospective study of patients who underwent surgical resection of syn-
chronous (nonbronchioloalveolar) non–small cell lung cancer.
Results: Between March 1996 and December 2009, 67 patients (30 men) underwent 121 operations. Forty-four
patients had bilateral tumors. Positron emission tomographic scans were performed in 58 (87%) patients,
computed tomographic scans and magnetic resonance imaging of the brain in 53 (79%), and mediastinoscopy
in 56 (84%). N2 lymph nodes were benign in all patients before undergoing resection of bilateral tumors of the
same histologic type. Types of resection were lobectomy in 62, sublobar in 73, and pneumonectomy in 1. Eleven
patients (16%) had postoperative morbidities. Cancer-specific 3- and 5-year survivals were 73% and 69%,
respectively, and overall 3- and 5-year survivals were 64% and 53%, respectively. Subgroup analysis demon-
strated no difference in overall survival at 5 years between bilateral tumors of the same histologic type (M1a)
(49%) versus different histologic types 42% (P¼ .88), or between bilateral tumors (50%) and ipsilateral tumors
(54%) (P ¼ .83).
Conclusions: The 5-year survival of surgically resected, synchronous, N2-negative, nonbronchioloalveolar,
non–small cell lung cancer is excellent, even in patients who have bilateral lung lesions that harbor the same
histologic features. Although the new TNM classification system labels this disease as clinical stage IV M1a,
survival acts more like a separate T1 lesion after surgical resection. Thus, surgical resection should be
considered in appropriately selected patients who have multiple pulmonary malignant tumors that are N2
negative. (J Thorac Cardiovasc Surg 2011;142:547-53)With improved imaging studies, particularly high-
resolution computed tomography (CT) and positron
emission tomography (PET), patients with lung cancer fre-
quently have more than 1 suspicious lung nodule. In many
instances, these tumors represent metastatic disease from
a single original tumor and are classified correctly by cur-
rent TNM classification as T3, T4, or M1a.1 Still other
possibilities include nonrelated synchronous multiple
primary lung cancers (SMPLC). Stedman’s Medical
Dictionary2 defines synchronous as ‘‘occurring simulta-
neously’’ and metachronous as ‘‘not synchronous; multiple
separate occurrences such as multiple primary cancers de-
veloping at intervals.’’ Few studies accurately or consis-
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limits the understanding of this clinical scenario. Past3
and present1 international systems for the staging of lung
cancer have added little to this issue, further leading to con-
fusion among physicians who care for such patients. Al-
though it can be inferred that different histologic features
would be classified independently, this is not true of tumors
of the same histologic classification. Presently, these dis-
ease states are defined as T3 (same lobe), T4 (ipsilateral
different lobe), or contralateral lung (M1a). However,
some of these multiple tumors are in fact synchronous
and unrelated even when histologically similar. When cur-
rent guidelines are implemented and dictate patient care,
this frequently results in undertreatment of potentially cur-
able SMPLC.
The primary objective of this study was to determine
long-term survival in patients who underwent complete sur-
gical resection of truly SMPLC in the hopes of clarifying
optimal treatment and to serve as a reference for future
study in this group of patients.METHODS
This is a multi-institutional retrospective cohort study of patients who
underwent surgical resection of synchronous lung cancer (non-BAC) be-
tween March 1996 and September 2009. The study received institutional
review board approval at all 3 participating institutions: Albany Medicalrdiovascular Surgery c Volume 142, Number 3 547
Abbreviations and Acronyms
CT ¼ computed tomography
BAC ¼ bronchioloalveolar cancer
MRI ¼ magnetic resonance imaging
PET ¼ positron emission tomography
SMPLC ¼ synchronous multiple primary lung
cancer
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SCenter, Albany, New York, Hospital of St Raphael, New Haven, Connect-
icut, and University of Alabama at Birmingham, Birmingham, Alabama.
Waiver of individual patient consent was granted.
All patients who underwent surgical resection of more than 1 non–small
cell lung cancer (NSCLC) were reviewed for possible inclusion. Patient de-
mographics, preoperative evaluation, surgical treatment, pathologic stage,
mortality, cancer-free survival, site of recurrence, overall survival, and
cause of death were primary end points and were identified by multiple
sources includingmedical records, follow-up radiographic studies, hospital
computer information systems, tumor registry, Social Security Death In-
dex, and, when necessary, telephone contact with patients or surviving fam-
ily members. Patients who did not meet the inclusion criteria were excluded
from further evaluation. Patients with SMPLC, by our inclusion criteria,
received 2 separate staging designations.Inclusion/Exclusion Criteria
Patients who were admitted with or were identified intraoperatively or
pathologically as having more than 1 tumor and who underwent surgical
resections with the intent of cure were eligible for inclusion in this study.
Patients with typical carcinoid tumors, BAC, or nonmalignant nodules
were excluded. Patients in whom metachronous pulmonary nodules devel-
oped were also excluded. Multiple ipsilateral tumors were included only if
the tumor had different histologic features. Ipsilateral tumors of the same
histologic type but different subtypes were excluded. Bilateral tumors of
the same histologic type were included in this study, provided mediastinal
evaluation proved N2 lymph node stations were benign. Bilateral tumors of
different histologic types with positive N2 lymph nodes were included in
this study.
Stages of disease were recorded according to the seventh edition of the
TNM classification. We reported a stage for each of the 136 tumors as if it
were a separate cancer and the other nodules were not present. If a patient
had a T2 and a T1 lesion in the same side of the chest, of different histologic
type, and 1 of the N1 lymph nodes was positive, both lesions were listed as
N1 if the specific histologic type of the N1 lymph node could not be deter-
mined, that is, T2 N1 M0 and the other T1 N1 M0.
Statistical analysis was completed using SAS 9.1 (SAS Institute, Inc,
Cary, NC). Continuous data are presented as means and categorical data
are presented as percentages. Fisher’s exact test or the Pearson c2 test was
used to assess categorical data and the Wilcoxon rank sum was used for
continuous data. Actuarial survival of patients was estimated by Kaplan-
Meier analysis, with P values calculated by log-rank statistics. For the
multivariable survival analysis, variables with a univariate P value< .08
were entered into a Cox stepwise proportional hazards model. Patients
alive at the end of the study period were censored for purposes of survival
analysis, and time-related events were calculated from the time of the ini-
tial procedure. Death from any cause was used to determine the overall
survival, and only cancer-related deaths were included in the cancer-
specific mortality. Recurrence of cancer was used to determine the
disease-free survival. Local recurrence was defined as recurrence of
tumor within the same lobe, regional recurrence was defined as the in-
volvement of mediastinal lymph nodes ipsilateral to the side of surgery,548 The Journal of Thoracic and Cardiovascular Surgand distant recurrence was defined as recurrence in the contralateral
lung or in the remaining lung on the same side but in a different lobe
from the one on which the operation was performed or tumor recurrence
elsewhere in the body. Operative deaths were included in the survival
analyses. Follow-up consisted of chest and abdominal CT every 6 months
for the first 2 years and yearly afterward. The final data acquisition was
December 2009.
RESULTS
Between March 1996 and September 2009, a total of
67 patients (30 men) underwent 121 surgical procedures
to resect 136 lung cancers. Patient characteristics are
shown in Table 1. Forty-four patients had bilateral tumors
and 23 had ipsilateral tumor locations as shown in
Figure 1. PET scans were performed in 58 (87%) patients
and CT/magnetic resonance imaging (MRI) of the brain
in 53 (79%) patients. N2 lymph nodes were determined
to be to be negative for metastatic disease in all patients
before resection of same-histology tumors. Tumor details
and pathologic stage are shown in Table 2. Mediastinal
(N2) lymph nodes were positive in 2 patients before re-
section of bilateral tumors of different histologic cell
type. Surgical resections included lobectomy in 62, sub-
lobar resection in 73, and pneumonectomy in 1 patient.
Median interval between operations for those with bilat-
eral tumors was 2.0 months. Of the 67 patients, 11
(16.4%) had major postoperative morbidities and 2
(2.9%) died after their second operative procedure. Oper-
ative mortality occurred in 2 (1.7%) of 121 surgical
resections.
Overall survival and cancer-specific survival are shown
in Figure 2. Cancer-specific 3- and 5-year Kaplan-Meier
survival was 73% and 69%, respectively, and overall 3-
and 5-year survival was 64% and 53%, respectively.
Univariate analysis demonstrated no difference in overall
survival at 5 years between bilateral tumors of the same his-
tologic type (M1a) (49%) versus different histologic types
(42%) (P ¼ .88) or between bilateral tumors (50%) and
ipsilateral tumors (54%) (P ¼ .83). Mean follow-up was
45.5 months.
Table 3 shows the results of the univariate analysis that
was performed to identify variables associated with sur-
vival. Analysis was performed both for overall survival
and for cancer-specific survival. There was a significant
difference based on highest pathologic stage for both
overall survival (P ¼ .001) analysis and cancer-specific
survival analysis (P ¼ .009). Additionally, there was
a trend toward significantly greater cancer-free survival
in patients who had all 3 preoperative staging tests (5-
year cancer-free survival 75% in patients who had all 3
preoperative tests and 57% in those that did not), but
these differences did not achieve statistical significance
(P ¼ .160). There were no significant differences in sur-
vival between men and women by age, histologic type,
or tumor location.ery c September 2011
TABLE 1. Patient characteristics for the 67 patients in this study
Age (mean years)  SD 70.9  8.7
Gender
Male 30 (45%)
Female 37 (55%)
FEV1% (mean)  SD 81%  19%
Neoadjuvant chemotherapy 8 (12%)
Adjuvant chemotherapy 9 (13%)
Preoperative staging
Mediastinoscopy 56 (84%)
Brain MRI 53 (79%)
FDG-PET scan 58 (87%)
SD, Standard deviation; FEV1%, percent forced expiratory volume in 1 second;MRI,
magnetic resonance imaging; FDG-PET, fluorodeoxyglucose positron emission
tomography.
TABLE 2. Tumor characteristics
No. of patients 67
Albany Medical Center 8
Hospital of St Raphael 32
University of Alabama, Birmingham 27
No. of tumors 136
Median number of tumors (range) 2 (2-3)
Histology 23
Ipsilateral tumors
Adenocarcinomaþsquamous 8
Adenocarcinomaþneuroendocrine 8
Adenosquamousþadenocarcinoma 3
Squamousþneuroendocrine 4
Bilateral tumors 44
Adenocarcinoma (multiple) 21
Squamous (multiple) 6
Adenocarcinomaþsquamous 8
Squamousþneuroendocrine 1
Adenosquamousþadenocarcinoma 2
Adenosquamousþsquamous 1
Adenocarcinomaþneuroendocrine 4
Adenosquamous (multiple) 1
Pathologic stage using 7th edition for all 136 tumors
IA 89
IB 32
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currence occurred in 16 (24%) patients and was local in 3
(19%), regional in 1 (6%), and distant in 12 (75%). Local
recurrence occurred in 3 (4%) of 73 sublobar resections.
Two of these 3 patients underwent completion lobectomy.
Metachronous multiple primary lung cancers developed in
3 (4%) patients, 2 of whom underwent surgical resection
with curative intent.FIGURE 1. Location of non–small cell lung cancer: A, all tumors; B, bi-
lateral tumors.
IIA 2
IIB 11
IIIA 1
IIIB 2
The Journal of Thoracic and CaDISCUSSION
Patients with multiple suspicious lung nodules are not un-
common. In many patients these tumors represent meta-
static lung cancer from a single original tumor and are
appropriately staged as T3 (same lobe), T4 (ipsilateral dif-
ferent lobe), or M1a (contralateral lung) disease according
to the most recent staging classification.1 Some of these pa-
tients, however, have SMPLCs, which are separate, distinct,0 12 24 36 48 60 72 84 96 108 120 132 144 156 168
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FIGURE 2. Kaplan-Meier survival curve depicting actual overall survival
(N¼ 67) and 5-year survival (52%). Lighter lines indicate 95% confidence
intervals.
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TABLE 3. Kaplan-Meier 5-year overall survival and cancer-specific survival based on patient factors
Five-year overall survival P value Five-year cancer-specific survival P value
Gender .438 .340
Male 53% (N ¼ 30) 76% (N¼ 23)
Female 50% (N ¼ 37) 64% (N ¼ 27)
Had all 3 preop staging tests (med, brain MRI, PET) .576 .160
Yes 56% (N ¼ 42) 75% (N ¼ 31)
No 44% (N ¼ 8) 57% (N ¼ 19)
Histology
Adenocarcinoma (multiple) 72% (N ¼ 22) .630 87% (N ¼ 17) .204
Squamous (multiple) 50% (N ¼ 6) 75% (N ¼ 4)
Adenocarcinomaþsquamous 39% (N ¼ 15) 61% (N ¼ 9)
Adenocarcinomaþother 55% (N ¼ 17) 68% (N ¼ 14)
Squamousþother 22% (N ¼ 6) 34% (N ¼ 6)
Adenosquamous (multiple) (N ¼ 1)*
Tumor location .831 .696
Ipsilateral 50% (N ¼ 23) 67%
Bilateral 54% (N ¼ 44) 71%
Highest clinical stage, 7th edition
IIB (T3 N0, T4 N0) 12% (N ¼ 6) .002 (N ¼ 1)* .024
IIIA (T3-4, N1-2, M0) 18% (N ¼ 16) 22% (N ¼ 4)
IIIB (T4 N2, Tx N3) (N ¼ 1)* (N ¼ 1)*
IV (bilateral) 72% (N ¼ 44) 72% (N ¼ 44)
Highest pathologic stage, 7th edition
IA 44% (N ¼ 81) .297 66% (N ¼ 51) .869
IB 70% (N ¼ 36) 78% (N ¼ 33)
IIA (N ¼ 3)* (N ¼ 2)*
IIB 64% (N ¼ 6) 63% (N ¼ 6)
IIIA 55% (N ¼ 7) 54% (N ¼ 7)
IIIB, IV (N ¼ 3)* (N ¼ 1)*
*Insufficient survival data to compute a meaningful result.
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Sand unrelated. Patients with SMPLCs are at risk of being
clinically overstaged and subsequently undertreated using
the sixth and even the current seventh TNM staging sys-
tems. In this study we sought to evaluate the long-term sur-
vival of patients undergoing resection of SMPLCs avoiding
pitfalls common to other recent studies.
The incidence of SMPLC is unknown but has been re-
ported to occur in 4.5%4 of patients with newly diagnosed
lung cancer and may be increasing.5 A better understanding
of these patients, their treatment options, and outcomes isFIGURE 3. The Kaplan-Meier overall 5-year sur
550 The Journal of Thoracic and Cardiovascular Surga critical part of providing the optimal treatment of this
not so uncommon clinical scenario. A lack of consistency
in definitions applied to overlapping clinical scenarios leads
to further confusion. This explains the wide range of pub-
lished results and confusion among physicians regarding
appropriate treatment of patients with SMPLC.
Martini and Melamed6 were the first to describe and cat-
egorize nuances associated with patients with multiple lung
cancers. Recent publications on the subject of SMPLC
have been inclusive rather than exclusive, often includingvival by side of resection and histologic type.
ery c September 2011
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Stypical carcinoid tumors, BACs, and ipsilateral tumors of
the same histologic type.7 Finley and associates7 recently
reported the largest series to date. In that retrospective
study, of 175 cases reviewed, most were ipsilateral
(59%) and only 34 (19%) were of a different histologic
type. This differs from our series by including what most
would describe as T3 and T4 tumors as SMPLC based on
retrospective histologic subtyping. Using retrospective his-
tologic subtyping, only 7 patients with same lobe (T3)
lesions were thought to be related and 27 (T3) lesions
were considered different and thus included in their analy-
sis. Other studies4 reporting on SMPLC include patients
who have second tumors develop within 2 years. These pa-
tients were considered to have metachronous multiple pri-
mary lung cancers and were excluded from our series.
Varying definitions of SMPLC have limited our understand-
ing and explain the wide range of published results. Pub-
lished 5-year survival for SMPLC over the past 10 years
typically ranges between 10%8 and 35%9 and is often cited
as 30%.10 When BAC tumors are included, the 5-year sur-
vival has been reported to be nearly 70%.11 Using our preop-
erative assessment and surgical strategies, our overall 5-year
survival was 53% and cancer-specific survival was 69%.
Our strict inclusion and exclusion criteria were designed to
minimize the risk of including metastatic secondary nodules
that might influence the understanding of outcomes related to
SMPLC. Our criteria appear to be validated by subgroup
analysis, which shows no survival difference between bilat-
eral and ipsilateral tumors, 50% and 54%, respectively
(P ¼ .83), or tumors of same or different histologic types,
49% and 42%, respectively (P ¼ .88). By design, our study
was more exclusive than others. Having done so, we believe
this report reflects the true expected outcomes for patients
undergoing resection of SMPLC who are N2 negative. Our
results also support using these criteria as the basis for future
study in SMPLC.
Patients who have more than 1 suspicious pulmonary
nodule should undergo thorough evaluation by a thoracic
surgeon. Appropriate preoperative assessment is critical
in patient selection and includes routine pulmonary func-
tion testing, CT scan of chest and upper abdomen, selective
cardiac and pulmonary assessment, and evaluation of other
comorbidities just as in any other patient being evaluated
for pulmonary resection. Although the merits of additional
routine testing including PET/CT, brain imaging, and surgi-
cal staging can be argued regarding many patients with sus-
pected lung cancer, we believe that in patients with
potential SMPLC every attempt should be made to exclude
metastatic disease and that routine use of these additional
studies is indicated before surgical intervention. Even in
the case of CT-negative and PET/CT-negative mediastinal
lymph nodes, these patients should still undergo formal sur-
gical staging with mediastinoscopy inasmuch as the possi-
bility of false-negative rates of PET/CT are reported asThe Journal of Thoracic and Ca15%.12 Endobronchial ultrasound is an alternative to me-
diastinoscopy, but this too may result in unacceptably
high false-negative rates,13 which have been reported by
us as high as 28%.14
Once selected for surgical resection, planning must take
into account location of tumor, pulmonary reserve, and
type of surgical resection planned. What constitutes an ap-
propriate surgical resection is influenced as much by what
the patient will tolerate as by what may be considered stan-
dard of care. We believe in using sublobar resections when
appropriate, especially for tumors less than 2 cm for these
patients. This approach was used in the resection of more
than half of the tumors presented here. The desired therapy
is a segmentectomy with margins that are at least equal to
the diameter the tumor, but for lesions that have visceral
pleural invasion or are greater than 2 cm we prefer lobec-
tomy. With emerging data on the cancer survival with ana-
tomic segmentectomy15 and our survival curves, this would
appear to be the prudent choice. Local recurrence is higher
with sublobar resection16 and occurred in 3 (4%) patients in
this series, 2 of whom underwent completion lobectomy.
All patients with bilateral tumors in this study were treated
by a staged surgical approach. We concede there are no data
to support staged approaches over simultaneous resection in
the treatment of bilateral SMPLC.
Despite being a multi-institutional study, shortcomings
still exist. No data were evaluated regarding possible
SMPLC that did not undergo surgical resection. We con-
cede the importance of BAC SMPLC; however, it encom-
passes a wide spectrum of disease and we chose to
exclude these patients to define outcomes in non-BAC
non–small cell lung cancer. Another weakness is the poten-
tially different surgical approaches between the different in-
stitutions and the different surgeons in the treatment of
these patients. As a result, no conclusions can be drawn re-
garding ideal surgical treatments.
Surgical resection of SMPLC is associated with better
than expected long-term survival and cure. Appropriate
evaluation is essential to identify these patients and to avoid
incorrectly assigning them to a more advanced disease
stage. After curative resection, these patients require close
surveillance for recurrent and new tumors that may be treat-
able. Adherence to a strict definition of SMPLC and modi-
fications in our present TNM classification regarding
tumors of the same histologic type is imperative to make
further inroads in the treatment of this all too common
situation.
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Dr Steven R. DeMeester (Los Angeles, Calif). I congratulate
Dr Fabian and coauthors on an excellent manuscript and
presentation.
In this study, the authors address a clinically important issue—
what to dowith SMPLC by assessing the survival after resection of
these simultaneous lesions. Although the title indicates that the pa-
tients were N2 node negative, there were in fact 2 patients who had
positive N2 nodes. Why were these patients included in your anal-
ysis? Were these patients who did not have mediastinoscopy?
Should mediastinoscopy be essential in all of these patients?
Dr Fabian. That is a good point. We elected to include them be-
cause they cover the gamut of the disease that we deal with. Both
patients had bilateral tumors. Both had mediastinoscopy preoper-
atively, which discovered single-station N2 disease. Both patients
underwent neoadjuvant therapy preoperatively, subsequent restag-
ing, and then resection.
Dr DeMeester. Second, you mentioned that the synchronous
cancers were detected preoperatively, intraoperatively, or on final
pathologic examination. Did you evaluate survival on the basis of
how the lesion was found? In other words, if it was found patholog-
ically, did that imply a different survival than if it was known552 The Journal of Thoracic and Cardiovascular Surgpreoperatively? Did the number of lesions affect survival in these
patients?
Dr Fabian. That is a very good point. We did not look at it.
We do know that in the overwhelming majority of our patients
in this series, we had the knowledge of preoperative diagnosis,
particularly 44 with bilateral tumors. As well as the majority
of the 18 ipsilateral lesions in different lobes. There were only
5 ipsilateral same lobe so I don’t think we could determine
much from these data. But I do think it is a good point and worth
considering.
Dr DeMeester. The data presented by your group as well as
from previous publications all show that the histologic type of
the lesions does not significantly affect survival. Do you recom-
mend making any attempt to identify the histologic type preoper-
atively, and why exclude patients with ipsilateral same-histology
lesions?
Dr Fabian. The reason for excluding ipsilateral same-histology
lesions is that the current surgical recommendations are widely es-
tablished in both T3 and T4 lesions. The purpose of excluding
those patients here was to confirm as best we were able what the
true survival was for synchronous and avoid falsely including sat-
ellite nodules and metastatic nodules.
Dr DeMeester. From a mechanistic standpoint, it is logical that
most patients with synchronous lung cancers that are indeed sec-
ond primary tumors should be cigarette smokers, whereas in pa-
tients who are not cigarette smokers, you may suspect these
other lesions represent metastatic lesions. How many patients in
this series were cigarette smokers and did you analyze the outcome
in nonsmokers to see whether indeed we should not be resecting
multiple lesions in nonsmokers?
Dr Fabian. That is a very interesting point. The patients from St
Raphael’s and Albany Medical Center all were smokers. I cannot
comment on the University of Alabama smoking percentage and
we did not look at that specifically. Although if we accept radon
as being the largest risk factor for nonsmoker development of
non-small cell lung cancer, I believe that they may also have the
risk for the development of synchronous tumors. The primary dif-
ference is the distribution, which I understand to be the lower lobe
lung fields.
DrDeMeester. Last, could you describe your operative strategy
for patients with preoperatively detected synchronous bilateral le-
sions? Was median sternotomy and simultaneous resection used,
or were these all staged procedures? How did the characteristics
of the lesions affect the surgical approach? How did you choose
to do lobectomy or bilobectomies versus lesser resections in these
patients?
Dr Fabian. All of the bilateral lesions were approached as
staged procedures. No sternotomies were performed. As far as pre-
operative planning, there are 2 approaches. My personal method is
to approach the tumor that is most likely to increase the stage of
disease and therefore obviate the need for the second operation.
Having said that, the majority of the other surgeons who included
their patients in this series took the opposite approach, which was
to deal with the smaller lesion that would most likely get the pa-
tient through the second operation: if it was a planned sublobar
or superior segementectomy on one side in a lobe, they would ap-
proach the smaller tumor first. We actually looked at whether or
not the lower pathologic stage versus the higher pathologic stageery c September 2011
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a trend, it did not meet statistical significance.
Dr Douglas E. Wood (Seattle, Wash). Dr Fabian, this was
a great presentation on a very important topic. I only wish you
were presenting it to a group of pulmonologists or medical oncol-
ogists rather than to this audience, which I think understands the
principles fairly well.
I agree with Dr DeMeester’s question about your exclusion of
ipsilateral same-histology tumors, which obviously are just as
likely to be synchronous tumors rather than satellite lesions. I think
you may have lost some numbers and some additional ability to
evaluate those. I guess I encourage you and Dr Cerfolio to poten-
tially reconsider that decision and to include those patients.
In our own practice, we have used the lack of N2 disease and the
lack of other metastatic disease as strong surrogates for synchro-
nous rather than metastatic cancers. That is similar to the conclu-
sion you have reached here; yet only a majority, but not every
patient, had a PET scan, mediastinoscopy, and brain MRI, which
would be the main criterion for eliminating the possibility that
these patients actually have metastatic disease. I think you ad-
dressed that in your conclusions, but can you reaffirm for me
what your principle is now for managing these patients? Would
they all receive each of those 3 modalities for lymph node and dis-
tant disease staging?
Dr Fabian. That is a valid point and thank you for your com-
ments. Specifically with regard to preoperative staging, it is crit-
ical that patients have both an integrated PET/CT scan as well as
mediastinoscopy and brain imaging, as you have pointed out.
Mediastinoscopy is probably the most critical component. In
my practice, I am not willing to substitute endobronchial ultra-
sound because of potential false-positive results. In the setting
of a PET scan that shows no evidence of mediastinal adenopathy,
I think those patients also need mediastinoscopy. My approach
is for all 3. However, I will give you an example of a patient.
In a patient with bilateral suspicious nodules, it wouldn’t be un-
reasonable to pursue a right side diagnostic thoracoscopy and
perform a lymphadenectomy if, in fact, it proves to be a malignant
nodule. I think for me in that patient it suffices to supplant the
mediastinoscopy in that particular scenario. As far as simple pro-
cedures preoperatively, I think mediastinoscopy should be used
routinely.
Dr Wood. I guess I would still argue that if you had done a me-
diastinoscopy and therewas a node positive, you could have forgone
the minimally invasive but still more invasive video-assisted tho-
racic surgical approach to pulmonary resection, which that patient
would not have benefited from, so you learned it retrospectively
rather than prospectively.
The last point I would make is to consider simultaneous proce-
dures in at least in some of these patients. Some patients can have
simultaneous rather than staged procedures even if they haveThe Journal of Thoracic and Cabilateral disease, without even a median sternotomy but with bilat-
eral approach. I would encourage you and Dr Cerfolio to add that
into your consideration for managing these patients.
Dr Fabian. I agree and again thank you for the comments. One
of the limitations of this study was in data supporting recommen-
dations regarding surgical approaches. I have no argument or data
to argue against simultaneous procedures and believe it is a per-
fectly acceptable way to treat these patients.
Dr Paul Schipper (Portland, Ore). My question is along the
same lines as Dr Wood’s and Dr DeMeester’s in thinking about
systemic versus localized disease. Suppose you have a patient
who has bilateral primaries and you think they are synchronous.
The N2 nodes are negative, and you have done the mediastino-
scopy and endobronchial ultrasound. When you resect the first
one, you find that there are in fact N1 nodes that are positive at
level 11 or level 12, or you find a third nodule that is of the
same histologic type, now an ipsilateral nodule. With this new ev-
idence of metastatic disease but no N2 disease, something consid-
ered less ominous in the staging system, would you continue on
with that second side at a later time or would you stop? Would
you say, this is systemic disease; maybe they need some chemo-
therapy and no more surgery?
Dr Fabian. I think that question runs the gamut. During the
bronchoscopy and mediastinoscopy, I try to establish the histo-
logic type of both lesions, whether with biopsy, brushings, or
washings this can be very helpful.
I think that, if a patient presented with T3 right upper lobe dis-
ease with the same histologic type, the indication is still for surgi-
cal resection of the contralateral side and we had patients in this
series like that. Of course, there are other considerations but
when falsely labeling someone with systemic or metastatic disease
ensures a poor outcome I think resection after prudent consider-
ation is still appropriate.
Dr Schipper. If the N1 node is positive at the time of your re-
section, would you resect the second lesion on the other side?
Dr Fabian. I would.
Dr Joseph Shrager (Stanford, Calif). You really went to great
pains to describe the tumors studied here as non-BAC, whereas to
me BAC is maybe even the more interesting group and certainly
the group we see more often. I am wondering how sure you are
they are actually non-BAC. Did you go back and have the pathol-
ogist look at the periphery of the tumors for a BAC component, or
did you reexamine the CT scans to see whether there was any
ground glass in the lesions?
Dr Fabian. We did, and I think that is a valuable question.
There are patients here whose pathology was reviewed, particu-
larly in the cases that were interpreted as adenocarcinoma with
BAC features but no BACs.
Dr Schrager. No pure BACs?
Dr Fabian. No pure BACs.rdiovascular Surgery c Volume 142, Number 3 553
